MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review

Date: March 15, 2016
Pages: 55
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M130417030AEN
Leaflet:

Download PDF Leaflet

MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review
MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

MediGene AG (MediGene) is a biotechnology company that carries out clinical research, development and marketing of novel drugs for the treatment of cancer and autoimmune diseases. The company's lead product, Veregen, is an ointment used to treat external genital warts. Its products in the developmental stage are EndoTag-1, being developed for the treatment of pancreatic cancer and triple-negative breast cancer (TNBC), completed its Phase II clinical trial stage; RhuDex, being developed for the treatment for autoimmune diseases, in Phase II clinical trial stage; and DC vaccine, being developed for prostate cancer is in phase II clinical trial. The vaccine is also being developed for acute myeloid lukaemia (AML) and is in phase I clinical trial. Its products in pre-clinical phase are TCR, TABS and AAVLP, which are being tested for cancer, leukaemia and autoimmune, and vaccine technology respectively. The company also develops innovative platform technologies for drug development. MediGene is headquartered in Martinsried, Germany.

MediGene AG Key Recent Developments

Feb 23, 2016: Medigene strengthens its DC platform with patent for treatment of stem cell or bone-marrow transplanted patients
Feb 16, 2016: Medigene secures additional viral vector production capacities for its clinical TCR studies
Jan 11, 2016: Medigene strengthens management with appointment of three Senior Vice Presidents
Dec 17, 2015: Medigene announces key Management Changes
Dec 08, 2015: Medigene: Promising data from Phase I/II IIT and Compassionate Use Programme with dendritic cell vaccines in AML presented at ASH Annual Meeting 2015

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

MediGene AG - Key Facts
MediGene AG - Key Employees
MediGene AG - Key Employee Biographies
MediGene AG - Major Products and Services
MediGene AG - Pharmaceutical Pipeline Products Data
MediGene AG, Pipeline Products by Therapy Area
MediGene AG, Pipeline Products by Development Phase
MediGene AG - History
MediGene AG - Company Statement
MediGene AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

MediGene AG - Business Description
MediGene AG - Corporate Strategy
MediGene AG - SWOT Analysis
SWOT Analysis - Overview
MediGene AG - Strengths
Strength - Lead Product- Veregen
Strength - Focused R&D Activities
Strength - Strong Partner Portfolio
MediGene AG - Weaknesses
Weakness - High Operating Expenses
Weakness - Dependence on Third Parties
MediGene AG - Opportunities
Opportunity - Acquisition of Trianta Immunotherapies GmbH
Opportunity - Strategic Agreements
Opportunity - Product Launches
MediGene AG - Threats
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Threat - Competitive Landscape
MediGene AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
MediGene AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 23, 2016: Medigene strengthens its DC platform with patent for treatment of stem cell or bone-marrow transplanted patients
Feb 16, 2016: Medigene secures additional viral vector production capacities for its clinical TCR studies
Jan 11, 2016: Medigene strengthens management with appointment of three Senior Vice Presidents
Dec 17, 2015: Medigene announces key Management Changes
Dec 08, 2015: Medigene: Promising data from Phase I/II IIT and Compassionate Use Programme with dendritic cell vaccines in AML presented at ASH Annual Meeting 2015
Nov 12, 2015: Medigene reports results for the first nine months of 2015
Nov 05, 2015: Medigene AG: Clinical data of Medigene's dendritic cell vaccines to be presented at ASH conference
Aug 06, 2015: Medigene publishes results for the first six months of 2015
May 28, 2015: US patent office prolongs term of Medigene's patent relating to dendritic cell (DC) vaccines to 2031
May 12, 2015: Medigene publishes results for the first three months of 2015

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

MediGene AG, Key Facts
MediGene AG, Key Employees
MediGene AG, Key Employee Biographies
MediGene AG, Major Products and Services
MediGene AG, Number of Pipeline Products by Therapy Area
MediGene AG, Number of Pipeline Products by Development Stage
MediGene AG, Pipeline Products By Therapy Area and Development Phase
MediGene AG, History
MediGene AG, Subsidiaries
MediGene AG, Key Competitors
MediGene AG, Ratios based on current share price
MediGene AG, Annual Ratios
MediGene AG, Interim Ratios
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
MediGene AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

MediGene AG, Pipeline Products by Therapy Area
MediGene AG, Pipeline Products by Development Phase
MediGene AG, Performance Chart (2010 - 2014)
MediGene AG, Ratio Charts
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: